Drug Profile
Research programme: biosimilars - ARA Healthcare
Alternative Names: ARABS 1; ARABS 2; ARABS 3; ARABS 4; ARABS 5; ARABS 6; ARABS 7; ARABS 8Latest Information Update: 24 Aug 2023
Price :
$50
*
At a glance
- Originator ARA Healthcare
- Class Enzymes; Interferons; Monoclonal antibodies; Recombinant proteins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer; Crohn's disease; Hairy cell leukaemia; Hepatitis C; Inflammation; Multiple sclerosis; Precursor cell lymphoblastic leukaemia-lymphoma; Rheumatoid arthritis
Most Recent Events
- 24 Aug 2023 Discontinued - Preclinical for Precursor cell lymphoblastic leukaemia-lymphoma in India (Parenteral)
- 24 Aug 2023 Discontinued - Preclinical for Rheumatoid arthritis in India (Parenteral)
- 24 Aug 2023 Discontinued for Cancer in India (Parenteral)